Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 8/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014472 | 0.85 | KDM5A (0.36) | CPB2KDM5AADA | |
| Hydrochloric Acid SCHEMBL9095682 | 0.81 | CPA1 (0.34) | CPB2CPA1CDK5CDK5R1 | |
| SCHEMBL2176873 | 0.77 | CYP2C9 (0.53) | CPB2HTT | |
| SCHEMBL11477981 | 0.76 | CPA1 (0.35) | CPB2CPA1CDK5CDK5R1KDM5A | |
| SCHEMBL19750174 | 0.76 | CPB2 (0.46) | CPB2CPA1 | |
| SCHEMBL16978267 | 0.76 | CPB2 (0.40) | CPB2CPA1CDK5CDK5R1KDM5A | |
| SCHEMBL6124221 | 0.74 | CPA1 (0.33) | CPB2CPA1CDK5CDK5R1KDM5A | |
| SCHEMBL24268206 | 0.73 | ADA (0.53) | KDM5AADA | |
| SCHEMBL1402037 | 0.73 | CYP2C9 (0.58) | CPB2CPA1CDK5CDK5R1 | |
| SCHEMBL2998713 | 0.72 | ALDH1A1 (0.37) | CPB2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH IP EE B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-2167474-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | Valletta Health IP EE B.V. (NL) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153385-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH B.V. (NL) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | UTS2R, UACA, HCAR1 | CPB2 903/4885CPA1 165/4885CDK5 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.